<DOC>
	<DOCNO>NCT02541058</DOCNO>
	<brief_summary>This study conduct develop evaluate cell-free fetal DNA test ( Ariosa Test ) non-invasive prenatal detection 22q11.2 chromosomal deletion duplication . Investigators evaluate subject abnormal U/S .</brief_summary>
	<brief_title>Non-Invasive Chromosomal Evaluation 22q11.2</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>DiGeorge Syndrome</mesh_term>
	<criteria>1 . Patient â‰¥18 year age able provide consent , age 18 , patient parental consent child assent provide required governing ethic committee . 2 . If pregnant , patient must singleton pregnancy least 10 week gestation time study blood draw . 3 . Patients must meet least one follow condition time enrollment : 1. pregnant abnormal fetal cardiac finding ultrasound undergoing evaluation prenatal genetic testing plan postnatal genetic test immediate newborn period ; 2. pregnant fetal ultrasound finding consistent 22q11.2 deletion/duplication phenotype undergo evaluation prenatal genetic testing plan postnatal genetic test immediate newborn period ; 3. pregnant fetus know 22q11.2 deletion/duplication confirm genetic testing documentation available ; 4. biologically related parent enrol child chromosomal deletion/duplication region 22q11.2 ; 4 . If site select enroll control patient , must pregnant woman undergo prenatal genetic evaluation 22q11.2 deletion/duplication . Exclusion Criteria Patients meeting follow criterion exclude study : 1 . Patient history malignancy treat chemotherapy and/or major surgery , bone marrow transplant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Velocardiofacial Syndrome</keyword>
	<keyword>Shprintzen Syndrome</keyword>
	<keyword>Conotruncal Defects</keyword>
	<keyword>Chromosomal Abnormalities</keyword>
	<keyword>22q , 22q.11.2</keyword>
	<keyword>deletion</keyword>
	<keyword>duplication</keyword>
</DOC>